The Australian pharmaceutical market is both highly competitive and highly regulated. There are many legal issues which a pharmaceutical company conducting business in Australia must contend with. This article examines general principles governing interlocutory relief, the impact of the Government pharmaceutical pricing regime, recent case law on interlocutory injunctions, and whether there is a trend in the granting of pharmaceutical interlocutory injunctions. This article is part of the PLC multi-jurisdictional guide to Life Sciences. For a full list of jurisdictional Q&As visit www.practicallaw.com/lifescienceshandbook.